common.study.topics.clinical

Novel Diagnostics for Early Lyme Disease

common.study.values.description

Novel Diagnostics for Early Lyme Disease

There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses. Definitive diagnosis is based on serum-based tests that have fundamental limitations: 1) current tests cannot detect early infections so patients do not receive antibiotic therapy until the infection has progressed, and 2) there is no way to measure if antibiotic therapy has been successful. MicroB-plex will address these two unmet clinical needs by introducing a novel, blood-based diagnostic method that will enable clinicians to diagnose infections earlier and to monitor the success of their interventions.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Diagnostic Test - MicroB-plex Lyme Immunoassay

Subject's blood and clinical data are collected to develop a diagnostic immunoassay

participant.views.study.view.additional

participant.views.study.view.scientific-title

Novel Diagnostics for Early Lyme Disease

common.study.values.clinical-trial-id

NCT03963635

participant.views.study.view.id

azpzqd